Pasteurellosis is a big respiratory disease of pigs worldwide caused by Pasteurella multocida which is a gram-negative bacterium. Our company is at the leading edge of the development of vaccines and therapeutics services since we utilize our resources with the purpose of expediting the progress of next-generation pasteurellosis solutions.
Introduction to Pasteurellosis
Pasteurellosis is a group of infectious diseases that is caused by bacteria belonging to the genus Pasteurella , especially by the Pasteurella multocida species. These Gram negative facultative bacteria cause great morbidity and mortality in pigs, cattle, sheep and birds, and even infect humans through animal bite and scratches.
The types of pasteurellosis are generally classified according to the host and disease effects. For example, in pigs it shows as progressive atrophic rhinitis (PAR) which is expressed as underdevelopment or complete absence of the nasal turbinates. Other forms include pneumonia in different animals and fowl cholera in poultry birds.
Fig.1 The growth conditions of the gdhA derivative Pasteurella multocida B:2 in YDB medium. (Oslan S. N. H., et al., 2022)
Vaccine Development for Pasteurellosis
Live-Attenuated Vaccine
Live-attenuated vaccines utilize a less virulent, yet still moderate bacteria which they are able to replicate safely. The gdhA mutant derivative of P. multocida B:2 is an example of such a mutant vaccine that exhibits great potential as an effective live vaccine candidate.
Subunit and DNA Vaccines
Subunit vaccines are constructed using selective bacterial proteins such as outer membrane proteins or toxins with the aim of provoking an immune response. DNA vaccine practices rely on plasmids containing antigen encoding, which serve as a catalyst for microorganism cells to uptake the antigen, hence igniting an immune response.
Inactivated Vaccines
Inactivated vaccines manipulate the immunity system by using inactivated bacteria or bacterial components and they are one of the most safe methods in developing vaccines. These vaccines in some cases contain adjuvants so as to improve their immunogenic efficacy.
Therapeutics Development for Pasteurellosis
Antibiotic therapy for the therapeutics of Pasteurellosis can include; ampicillin, ceftiofur, enrofloxacin and tulathromycin. Different strains from varying regions may have different bacterial susceptibility profiles that may impact the antibiotic selection process. Immunostimulants or other substances that tailor the immune response of the host in order to increase the availability of the bacteria have traditionally complemented the use of antibiotics.
We are pleased to be able to provide a full range of services in the development of pasteurelosis therapy. In case you would like to know more about us, please follow the link below.
Our Services
We employ an advanced understanding of pasteurellosis alongside novel technologies to provide solutions that are both cutting edge and vigorous. Furthermore, our solutions are encompassing as we seek to present vaccines along with pasteurellosis therapies.
Disease Models
- Pasteurella haemolytica Infection Mouse Models: Inbred C57 black mice
- Pasteurella multocida Infection Rat Models: Sprague-Dawley (SK/WDY) rats
- Pneumonic Pasteurellosis Infection Calves Models
Our development services are largely hinged on preclinical research which we regard to be critical for various stages of vaccine and therapy development. Reach out to us if you feel the need to utilize our services.
References
- Oslan, Siti Nur Hazwani, et al. "Pasteurellosis vaccine commercialization: physiochemical factors for optimum production." Processes 10.7 (2022): 1248.
- Register, Karen B., and Susan L. Brockmeier. "Pasteurellosis." Diseases of swine (2019): 884-897.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
